RT Journal Article SR Electronic T1 CD40L-Transfected Myeloma Cells Transfer Prolonged Immunity In Vivo JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 45 OP 48 VO 24 IS 1 A1 YOUNG KIM A1 JOHN W. STREHL A1 ELISABETH SIEVERS A1 MARCUS GORSCHLÜTER A1 PETER BROSSART A1 INGO G.H. SCHMIDT-WOLF YR 2010 UL http://iv.iiarjournals.org/content/24/1/45.abstract AB Background: In a large number of patients with multiple myeloma, chemotherapy is the only therapeutic option. During recent years, major effort has been put into immunotherapeutic approaches for this malignancy. Materials and Methods: In this study, wild-type (wt) myeloma cells (5×105) were injected subcutaneously into Balb/c mice. CD40L-transfected myeloma cells (5×105) were subsequently injected intratumorally into the established (>100 mm3) wt tumor nodules. Overall survival and tumor growth were measured. Results: Out of eight animals receiving wt tumor cells, one died prior to the formation of a solid tumor nodule. Following the CD40L-transfected myeloma cell injection, stable complete remission at day 60 with all the animals surviving resulted. On day 60, a re-challenge was performed with wt myeloma cells. No tumor growth was observed after 120 days out of seven remaining animals, one died. Conclusion: Intratumoral injection of CD40L-transfected myeloma cells induces complete tumor remission and long lasting immunity against tumor recurrence. Copyright © 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved